Find a Doctor

LS
Areas of Expertise

Lin F. Shen

Peking University Cancer Hospital & Institute

Bio

Lin Shen is in Beijing, China. They have been an author on 629 peer reviewed articles and participated in 17 clinical trials in the past 15 years.

Areas of Expertise

Contact

52 Fucheng Road
Beijing, 10014, CN

Latest Advances

Latest Advance
Study
  • Condition: Gastric Cancer (GC) in China
  • Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • Treatment Used: Third-Line Treatment
  • Number of Patients: 0
  • Published —
This article discusses the progress of third-line treatment for advanced gastric cancer (GC) in China.
Latest Advance
Study
  • Condition: Pancreatic Neuroendocrine Tumors (NETs)
  • Journal: The Lancet. Oncology
  • Treatment Used: Surufatinib
  • Number of Patients: 264
  • Published —
This study evaluated the effectiveness and safety of surufatinib in patients with advanced pancreatic neuroendocrine tumors (type of tumor that arises from specialized body cells called neuroendocrine cells; NETs).
Latest Advance
Study
  • Condition: Advanced Extrapancreatic Neuroendocrine Tumors
  • Journal: The Lancet. Oncology
  • Treatment Used: Surufatinib
  • Number of Patients: 198
  • Published —
This study tested the safety and efficacy of using surufatinib to treat patients with advanced extrapancreatic neuroendocrine tumors.
Latest Advance
Study
  • Condition: Gastric or Gastroesophageal Junction Adenocarcinoma
  • Journal: BMC cancer
  • Treatment Used: Sintilimab with Oxaliplatin/capecitabine
  • Number of Patients: 20
  • Published —
In this study, researchers evaluated the safety and effectiveness of sintilimab with oxaliplatin/capecitabine for the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma.
Latest Advance
Study
  • Condition: Advanced Solid Tumors
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Tislelizumab
  • Number of Patients: 300
  • Published —
The study researched the use of Tislelizumab in treating Chinese patients with advanced solid tumors.
Latest Advance
Study
  • Condition: Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Camrelizumab as Second-Line Therapy
  • Number of Patients: 607
  • Published —
This study assessed the safety and effectiveness of anti-PD-1 antibody, camrelizumab, versus investigator's choice of chemotherapy in previously treated patients with advanced or metastatic esophageal squamous cell carcinoma.
Latest Advance
Study
  • Condition: Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
  • Journal: Cancer
  • Treatment Used: Etoposide and Cisplatin or Irinotecan and Cisplatin
  • Number of Patients: 144
  • Published —
This study compared the efficacy and toxicity of etoposide and cisplatin (EP) and irinotecan and cisplatin (IP) as first-line treatment in patients with advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC).
Latest Advance
Study
  • Condition: Chemo-Refractory Gastric Cancer
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Toripalimab (TMB), a PD-1 Antibody
  • Number of Patients: 76
  • Published —
This study investigated the safety and effectiveness of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), and the predictive survival benefit of tumor mutational burden and PD-L1.
Latest Advance
Study
  • Condition: Gastric Cancer Prevention
  • Journal: BMJ (Clinical research ed.)
  • Treatment Used: Helicobacter Pylori Treatment and Vitamin and Garlic Supplementation
  • Number of Patients: 2258
  • Published —
This study assessed the effects of Helicobacter pylori treatment, vitamin supplementation, and garlic supplementation in the prevention of gastric cancer.
Latest Advance
Study
  • Condition: Advanced Gastric Cancer
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Toripalimab
  • Number of Patients: 76
  • Published —
The study evaluated the effectiveness of toripalimab ( specific chemotherapy drug) to treat patients with advanced gastric cancer (AGC).
Latest Advance
Study
  • Condition: HER2-positive metastatic gastric or gastroesophageal junction cancer
  • Journal: Cancer chemotherapy and pharmacology
  • Treatment Used: Pertuzumab
  • Number of Patients: 374
  • Published —
The study researched the outcomes of using Pertuzumab to treat HER2-positive metastatic gastric or gastroesophageal junction cancer.
Latest Advance
Study
  • Condition: Metastatic gastric or gastro-oesophageal junction cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: pertuzumab, trastuzumab and chemotherapy
  • Number of Patients: 3287
  • Published —
This study assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer.
Latest Advance
Study
  • Condition: Metastatic colorectal cancer
  • Journal: Future oncology (London, England)
  • Treatment Used: Aflibercept plus FOLFIRI
  • Number of Patients: 332
  • Published —
This study investigated whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could benefit patients with metastatic colorectal cancer.
Latest Advance
Study
  • Condition: Advanced Gastric Cancer
  • Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • Treatment Used: paclitaxel/capecitabine versus cisplatin/capecitabine
  • Number of Patients: 320
  • Published —
The purpose of the study was to compare the effectiveness and safety of paclitaxel/capecitabine therapy followed by capecitabine for maintenance versus cisplatin/capecitabine therapy in advanced gastric cancer.
Latest Advance
Study
  • Condition: Colorectal Cancer With Lung Metastasis (LM)
  • Journal: Clinical colorectal cancer
  • Treatment Used: Palliative Local Treatments and Different Pharmacotherapies
  • Number of Patients: 2233
  • Published —
This study investigated the role of palliative local treatments in prolonging survival and the effectiveness of different pharmacotherapies in colorectal cancer patients with initial lung metastasis (LM).
Latest Advance
Study
  • Condition: Metastatic Adenocarcinoma of the Pancreas
  • Journal: BMC cancer
  • Treatment Used: Nab-Paclitaxel Plus Gemcitabine
  • Number of Patients: 83
  • Published —
This study tested the safety and efficacy of treating metastatic adenocarcinoma of the pancreas with a novel, weekly, nab-paclitaxel plus gemcitabine therapy.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 30
  • Start Date: December 7, 2020
A Phase II, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN026 in Combination With KN046 in Patients With Locally Advanced Unresectable or Metastatic HER2-positive Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 282
  • Start Date: October 6, 2020
A Two-stage,Multi-center,Open-label, Randomized,Controlled Trial Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 159
  • Start Date: October 2020
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 96
  • Start Date: August 24, 2020
A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 590
  • Start Date: January 20, 2020
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of QL1203 and Placebo Respectively Combined With Chemotherapy in Patients With Metastatic Colorectal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 24
  • Start Date: September 26, 2019
A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 50
  • Start Date: March 26, 2019
An Open Lable, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 60
  • Start Date: August 13, 2018
Clinical Trial on the Tolerance and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Advanced Solid Tumor on Phase I
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 40
  • Start Date: July 27, 2018
Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma

All Publications
View All

Publication
Study
  • Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • Published —
Current status and research progress of third-line treatment for patients with gastric cancer in China
Publication
Study
  • Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • Published —
Pulmonary mucosa-associated lymphoid tissue lymphoma concurrent with lung squamous cell carcinoma: a case report and literature review

Contact

52 Fucheng Road
Beijing, 10014, CN

Insurance

Contact them to find out if they accept your insurance plan.